Clear Search sequence regions


  • humans (1)
  • myofibroblast (5)
  • patients (1)
  • research (1)
  • signal (1)
  • Sizes of these terms reflect their relevance to your search.

    Idiopathic pulmonary fibrosis is a lethal, progressive, and irreversible condition that has become a significant focus of medical research due to its increasing incidence. This rising trend presents substantial challenges for patients, healthcare providers, and researchers. Despite the escalating burden of pulmonary fibrosis, the available therapeutic options remain limited. Currently, the United States Food and Drug Administration has approved two drugs for the treatment of pulmonary fibrosis-nintedanib and pirfenidone. However, their therapeutic effectiveness is limited, and they cannot reverse the fibrosis process. Additionally, these drugs are associated with significant side effects. Myofibroblasts play a central role in the pathophysiology of pulmonary fibrosis, significantly contributing to its progression. Consequently, strategies aimed at inhibiting myofibroblast differentiation or promoting their dedifferentiation hold promise as effective treatments. This review examines the regulation of myofibroblast dedifferentiation, exploring various signaling pathways, regulatory targets, and potential pharmaceutical interventions that could provide new directions for therapeutic development. © 2024. The Author(s).

    Citation

    Xuetao Ju, Kai Wang, Congjian Wang, Chenxi Zeng, Yi Wang, Jun Yu. Regulation of myofibroblast dedifferentiation in pulmonary fibrosis. Respiratory research. 2024 Jul 18;25(1):284

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 39026235

    View Full Text